In the Sponsor-Investigator's discovery human subjects' study, the investigators will use the ABIRATERONE plus PREDNISONE plus ENZALUTAMIDE (300 patients - Group 1) or the ABIRATERONE plus PREDNISONE plus NILANDRON (300 patients - Group 2) to treat Prostate Cancer patients and will try to look for the relationship between the ABIRATERONE ACETATE TABLET therapeutic efficacy and the drug target CYP17 SNP Genotyping, and the relationship between the ABIRATERONE ACETATE TABLET therapeutic safety and the drug target CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 SNP Genotyping.